TLR2 and ischemic stroke: This dual action—attenuating MyD88-dependent cytokine storms and stabilizing vascular integrity—aligns with ischemic stroke pathophysiology, particularly in subacute phases where controlled Tlr2 inhibition may balance inflammatory resolution and angiogenesis.